ASH News Daily 2012 - Saturday, December 8, 2012 - (Page A-7)
T:21.5”
BECAUSE THE CONSEQUENCES
CAN BE DEVASTATING1-4
70%
aHUS
of aHUS patients (with the most common mutation*) die, require dialysis, or have
permanent renal damage within 1 year4
*CFH mutations = most common mutations4
• In aHUS, uncontrolled complement activation leads to systemic thrombotic
microangiopathy (TMA)4,10-14
• 33% to 40% of all patients die or progress to end stage renal disease with the fi rst clinical manifestation4,10
• Plasma exchange/infusion (PE/PI) does not address chronic, uncontrolled
complement activation, the underlying cause of TMA in aHUS10,13,15-20
• Differential diagnosis of aHUS is warranted9
aHUS = atypical hemolytic uremic syndrome
Visit Alexion booth #2513 at ASH December 8-11, Georgia World Congress Center, Atlanta, GA, for more
information and to pick up a videobook and USB key containing further details about PNH and aHUS.
For more information about PNH and aHUS, visit
www.PNHSource.com and www.aHUSSource.com
F:10.75”
© 2012, Alexion Pharmaceuticals, Inc. All rights reserved. SOL-1405
11/13/12 3:42 PM
Table of Contents for the Digital Edition of ASH News Daily 2012 - Saturday, December 8, 2012
ASH News Daily 2012 - Saturday, December 8, 2012
https://www.nxtbookmedia.com